Dermatology Times

?? Happy Thanksgiving from all of us at Dermatology Times. Today, we’re especially grateful for our global audience, esteemed contributors, and network of insightful clinicians who inspire and inform us daily. Thank you for being an integral part of our community.

?? FROM OUR PUBLICATION: Many dermatologists have charities to which they would like to donate, but they are not sure of the best way to do so, tax-wise. David Mandell, JD, MB, and Carole Foos, CPA, address a tool that can effectively achieve 2-fold benefits: the charitable remainder trust. ?? Read more: https://lnkd.in/g5YcJ9Fn

???? CONFERENCE HIGHLIGHTS: Catch up on Dermatology Times' coverage from the 22nd annual Society of Dermatology Physician Associates (SDPA) Fall Dermatology Conference in Las Vegas, Nevada. ?? Explore expert insights and interviews, reports on poster data, and more: https://lnkd.in/gBSrMD5P

?? STUDY: A recent study shed light on immune checkpoint inhibitor-induced pancreatic injury, a lesser-understood adverse effect associated with immune checkpoint inhibitors used in melanoma treatment. Despite its low occurrence rate (0.5% to 3%), the condition can lead to complications, such as pancreatic insufficiency, particularly when undiagnosed in asymptomatic patients. ?? Read more: https://lnkd.in/g3qy3vds

?? NEW DATA:?New methodological data presents the frequency, incidence, and prevalence of skin cancer in patients who have undergone heart transplantation. Skin cancer, including squamous cell carcinoma and basal cell carcinoma, is the most prevalent non-lymphoid malignancy occurring during heart transplantation follow-up. ?? Read more: https://lnkd.in/gp3CFrJu

???? Dermatology Times is excited to share that our digital supplement spotlighting innovations and insights in chronic hand eczema is live! Explore key data, test your knowledge in an interactive quiz, and more. ?? Visit our website to download and view now: https://lnkd.in/gfFUwy74

?? CASE-BASED PEER PERSPECTIVE: What are the key differences between plaque psoriasis and eczema? E. James Song, MD, FAAD, explains diagnostic insights. Watch now: https://ow.ly/u0t950Uf0O7

??ICYMI: Protagonist Therapeutics recently announced that PN-881 has been identified as a development candidate for immune-mediated skin diseases, positioning it as a potential best-in-class oral interleukin-17 antagonist. They stated this innovative therapeutic represents a promising advance in the treatment of dermatologic conditions driven by IL-17 pathways, including psoriasis. ?? Read more: https://lnkd.in/ggR28yjF

?? IN REVIEW:?A study in Asian populations found deucravacitinib effective for plaque psoriasis, outperforming apremilast and matching biologics in PASI responses. Deucravacitinib achieved PASI 75 in 66% and PASI 90 in 40% of patients. ?? Read more: https://lnkd.in/g5EPP4Qj

?? IN REVIEW:?Brodalumab (Siliq; Bausch Health Companies Inc.) demonstrates comparable efficacy and equal benefit in adult patients with psoriasis regardless of weight. Researchers reported similarities in treatment efficacy and lesion clearance in patients weighing less than 100 kg and greater than 100 kg. ?? Read more: https://lnkd.in/gzbgMKfB